Concepedia

Publication | Open Access

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

DOIFull Paper Access

36

Citations

16

References

2013

Year

J. Hun Hah, Mei Zhao, Curtis R. Pickering, Mitchell J. Frederick, Genevieve A. Andrews, Samar A. Jasser, David Fooshee, Zvonimir L. Milas, Chad E. Galer, Daisuke Sano,
Head & Neck

Abstract

Activating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line.

References

YearCitations

Page 1